Ovaterra launches anti-inflammatory supplement targeting fertility support
Ovaterra has released Ovamune, a new supplement designed to provide antioxidant and anti-inflammatory support for women focused on fertility.
New York-based Ovaterra has introduced Ovamune, a dietary supplement formulated to support immune health and reduce inflammation. The product is marketed specifically toward women over 35 who are navigating fertility journeys.
The company stated that the supplement is intended to function as a companion to existing prenatal vitamin regimens rather than a replacement. The formulation focuses on delivering antioxidants to address specific health concerns often associated with aging and reproductive health.
This release enters a competitive prenatal and fertility supplement market, where manufacturers are increasingly segmenting products by age and specific physiological needs. The addition of Ovamune reflects a broader industry trend toward personalized nutritional support for women of advanced reproductive age.